

(19)



(11)

**EP 3 674 314 B8**

(12)

**CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:

**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 73**

(51) International Patent Classification (IPC):

**C07K 14/47** <sup>(2006.01)</sup>      **A61K 47/54** <sup>(2017.01)</sup>  
**A61K 47/60** <sup>(2017.01)</sup>      **C07K 19/00** <sup>(2006.01)</sup>  
**A61K 38/00** <sup>(2006.01)</sup>

(48) Corrigendum issued on:

**12.07.2023 Bulletin 2023/28**

(52) Cooperative Patent Classification (CPC):

**C07K 14/47; A61K 38/10; A61K 47/542;**  
**A61K 47/60; A61P 9/00; A61P 9/04; A61P 9/12;**  
**A61K 38/00; C07K 2319/30**

(45) Date of publication and mention of the grant of the patent:

**03.05.2023 Bulletin 2023/18**

(21) Application number: **19211432.0**

(22) Date of filing: **10.06.2015**

(54) **APELIN POLYPEPTIDES**

APELINPOLYPEPTIDE

POLYPEPTIDES D'APÉLINE

(84) Designated Contracting States:

**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB**  
**GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO**  
**PL PT RO RS SE SI SK SM TR**

- **FROHN, Michael J.**  
Thousand Oaks, CA 91362 (US)
- **LANMAN, Brian Alan**  
Woodland Hills, CA 91367 (US)
- **REED, Anthony B.**  
Newbury Park, CA 91320 (US)
- **MIRANDA, Leslie P.**  
Thousand Oaks, CA 91362 (US)
- **ALLEN, John Gordon**  
Thousand Oaks, CA 91320-1799 (US)
- **PICKRELL, Alexander J.**  
Westlake Village, CA 91361 (US)
- **SIEGMUND, Aaron C.**  
Ventura, CA 93003 (US)
- **PENNINGTON, Lewis D**  
Arlington, MA 02474 (US)
- **YANG, Bryant**  
Agoura Hills, CA 91301 (US)

(30) Priority: **10.06.2014 US 201462010322 P**

(43) Date of publication of application:

**01.07.2020 Bulletin 2020/27**

(60) Divisional application:

**23171158.1**  
**23171189.6**

(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:

**15797720.8 / 3 155 002**

(73) Proprietor: **Amgen Inc.**

**Thousand Oaks, CA 91320-1799 (US)**

(74) Representative: **Dörries, Hans Ulrich**

**df-mp Dörries Frank-Molnia & Pohlman**  
**Patentanwälte Rechtsanwälte PartG mbB**  
**Theatinerstrasse 16**  
**80333 München (DE)**

(72) Inventors:

- **HOLDER, Jerry Ryan**  
Simi Valley, CA 93065 (US)
- **SWAMINATH, Gayathri**  
Brisbane, CA 94005 (US)

(56) References cited:

**WO-A1-2012/125408      WO-A1-2013/106437**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 3 674 314 B8**

US-A1- 2014 155 315

- JEAN-FRANÇOIS MARGATHE ET AL: "Structure-Activity Relationship Studies toward the Discovery of Selective Apelin Receptor Agonists", JOURNAL OF MEDICINAL CHEMISTRY, vol. 57, no. 7, 10 April 2014 (2014-04-10) , pages 2908-2919, XP055257810, US ISSN: 0022-2623, DOI: 10.1021/jm401789v
- ALEXANDRE MURZA ET AL: "Elucidation of the Structure-Activity Relationships of Apelin: Influence of Unnatural Amino Acids on Binding, Signaling, and Plasma Stability", CHEMMEDCHEM, vol. 7, no. 2, 6 February 2012 (2012-02-06), pages 318-325, XP055072892, ISSN: 1860-7179, DOI: 10.1002/cmdc.201100492
- ZHANG YANYAN ET AL: "Identifying structural determinants of potency for analogs of apelin-13: Integration of C-terminal truncation with structure-activity", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 22, no. 11, 13 April 2014 (2014-04-13), pages 2992-2997, XP028660063, ISSN: 0968-0896, DOI: 10.1016/J.BMC.2014.04.001
- A. L. BRAME ET AL: "Design, Characterization, and First-In-Human Study of the Vascular Actions of a Novel Biased Apelin Receptor Agonist", HYPERTENSION., vol. 65, no. 4, 1 April 2015 (2015-04-01), pages 834-840, XP055257809, US ISSN: 0194-911X, DOI: 10.1161/HYPERTENSIONAHA.114.05099